>亚太地区精神病学/抑郁症药物基因组学测试市场，按类型（焦虑症、情绪障碍、抑郁症、双相情感障碍、精神病性和饮食失调症）、测试类型（全基因组测序和基于染色体阵列的测试）、患者类型（儿童、成人和老年人）、基因类型（CYP2C19、CYP2C9、VKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT 等）、产品（仪器、消耗品、软件和服务）、最终用户（医院和诊所、诊断实验室、学术和研究机构等）、分销渠道（直接招标、第三方分销医院药房等）划分 - 行业趋势和预测到 2029 年。
亚太地区精神病学/抑郁症药物基因组学检测市场分析与洞察
药物基因组学检测通过提供有关人体如何代谢药物的信息来帮助医疗专业人员。这些信息可以帮助医生和其他人避免开出可能产生不良后果的抗抑郁药。药物基因组学在预测抗抑郁药对治疗重度抑郁症 (MDD) 的反应和耐受性方面表现出良好的前景。药物基因组学可以通过指导抗抑郁药的选择和剂量来改善临床结果。生物技术行业的不断发展和医疗支出的增加加速了精神病学/抑郁症对药物基因组学检测的需求。
癌症患病率的不断上升、治疗抑郁症和/或其他精神疾病的新技术正在增加药物遗传学检测在精神病学/抑郁症设备和程序中的应用，以及对非手术程序的日益偏好是推动预测期内市场需求的主要驱动因素。然而，与测试相关的高成本、严格的监管和缺乏认识可能会阻碍预测期内药物遗传学检测在精神病学/抑郁症市场的增长。
Data Bridge Market Research 分析称，亚太地区精神病学/抑郁症药物基因组学检测市场预计到 2029 年将达到 3.7542 亿美元的价值，预测期内的复合年增长率为 10.6%。由于亚太地区人口的抑郁症发病率不断上升，焦虑症成为市场中最大的类型细分市场。本市场报告还深入介绍了定价分析、专利分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
亚太地区精神病学/抑郁症药物基因组学测试市场，按应用（新型候选药物、药物优化和再利用临床前测试和批准、药物监测、寻找新疾病相关靶点和途径、了解疾病机制、汇总和综合信息、假设的形成和验证、从头药物设计、寻找旧药的药物靶点等）、技术（机器学习、深度学习、自然语言处理等）、药物类型（小分子和大分子）、产品（软件和服务）、适应症（免疫肿瘤学、神经退行性疾病、心血管疾病、代谢疾病等）、最终用途（合同研究组织 (CRO)、制药和生物技术公司、研究中心和学术机构等） |
|
覆盖国家 |
中国、日本、印度、韩国、新加坡、泰国、马来西亚、澳大利亚、越南、菲律宾、印度尼西亚和亚太地区其他地区 |
|
涵盖的市场参与者 |
- Genelex（Invite 公司的一部分）、Genewiz（Azenta Life Sciences 的一部分）、MD Labs、BiogeneiQ, Inc.、ONEOME, LLC、Myriad Genetics, Inc.、GenXys、Castle Biosciences, Inc.、PacBio、QIAGEN、Thermo Fisher Scientific Inc.、AB-Biotics, SA、Coriell Life Sciences、Eurofins Scientific、Illumina, Inc.、Dynamic DNA Laboratories、STADAPHARM GmbH、Color、cnsdose、Genomind, Inc.、Healthspek、myDNA Life Australia Pty Ltd.、HudsonAlpha、Sonic Healthcare Limited 等。 |
亚太地区精神病学/抑郁症药物基因组学检测市场定义
药物基因组学测试最近已变得可扩展并可用于指导重度抑郁症 (MDD)。临床医生越来越多地认识到药物基因组学 (PGx) 测试是指导精神疾病用药决策的重要工具。在预测期内，PGx 测试的广泛实施将推动市场的发展。
个性化医疗、分层医疗和精准医疗等术语与药物遗传学密切相关，但这些术语含义更广，还涵盖了其他非遗传因素。尽管如此，药物遗传学是这些领域的重要组成部分。药物遗传学主要关注人类生殖系 DNA 变异，但最近在理解情绪障碍和精神疾病方面也取得了进展。
药物遗传学测试研究药物与人体基因反应之间的相互作用，并寻找影响药物效果的基因变异。由于许多研究人员和科学家确定了药物与个体基因之间的独特相互作用，并提供了有价值的见解，随后可用于开发定制或个性化药物，因此该测试的需求量很大。
亚太地区精神病学/抑郁症药物基因组学检测市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 精神病和抑郁症患者数量增加
抑郁症是全球常见的疾病，估计有 3.8% 的人口受其影响，其中成年人为 5.0%，60 岁以上的成年人为 5.7%。抑郁症可能成为一种严重的健康状况，从轻度到极度严重，使人遭受巨大痛苦，在最坏的情况下可能导致自杀。尽管有超过 45 种抗抑郁药可供选择，但疗效不佳是一个挑战，被认为是遗传变异、精神病学/抑郁症的结果。根据抑郁发作的严重程度和模式，医疗保健提供者可能会提供心理诊断，如行为激活、认知行为疗法、人际心理治疗和/或抗抑郁药物，如选择性血清素再摄取抑制剂 (SSRI) 和三环类抗抑郁药 (TCA)。治疗这种精神障碍的药物各不相同。
随着抑郁症患病率的上升，药物基因组学检测的需求也在增加，因为它研究基因变异的影响，旨在提供个性化诊断。预计市场在森林期将增长。
- 个性化和精准医疗需求上升
药物基因组学测试可帮助医疗专业人员为患者选择最佳药物，因为该测试可以寻找可能影响药物效果的基因变异。
医疗正变得越来越个性化，患者逐渐对个性化医疗的疗效和副作用越来越感兴趣。个性化医疗有可能定制具有高安全范围和最佳反应的治疗方案。这一趋势很大程度上是由基因组测序的改进推动的。
个性化医疗保健的发展意味着药品生产方式的改变。制造商正从生产小分子药物转向小分子药物和基因疗法相结合。赞助商专注于通过投资新技术和生产个性化药物来取代低效的大规模批量生产。
克制
- 缺乏熟练的医疗和基因组学专家
大多数临床医生仍然对药物基因组学 (PGx) 检测和随后的数据解释缺乏信心，表明他们在这方面的知识不足。这强调了需要提高医疗专业人员对药物基因组学 (PGx) 检测的专业知识的理解能力。
医生对药物基因组学可能性的认识不足以及对测试结果的解释不充分或不充分也降低了针对患者的个性化技术。除了在医学院开展专题培训课程外，还需要在继续专业教育系统中开展教育周期并为执业医生免费提供信息：学术互联网门户网站、网络研讨会等。临床药理学家在药物基因组学测试的实施中起着至关重要的作用。
临床药理学家在药物遗传学领域的能力至关重要：他或她是组织基因分型在临床实践中的应用、解释测试并告知医生药物遗传学对特定疾病分类患者的可能性的人，在引入药物遗传学的过程中充当科学界、医疗保健系统和执业医师之间的主要纽带。
机会
-
技术不断进步
药物基因组学的进步为将个性化医疗引入精神疾病临床实践带来了越来越多的机会。个性化医疗可以定义为一种全面的前瞻性方法，以预防、诊断、治疗和监测疾病，从而实现最佳的个人医疗保健决策。随着医疗保健技术的进步，目前有 100 多种药物含有美国食品药品管理局 (FDA) 标签，这些标签与可能适用的药物基因组生物标志物有关。此外，正在开发新的和先进的方法来促进抑郁症样疾病的药物基因组学检测。这些测试使用先进的基因检测方法提供精确的结果以形成治疗方案。支持测试的技术改进提高了测试选项的可访问性，越来越多的资源帮助临床医生了解如何在可用时使用这些信息，这使得个性化或精准医疗的这一方面成为现实。因此，提供者需要更多地了解药物基因组学测试的科学和临床相关性。
这些测试还有助于建立药物与个人基因构成之间的有意义关系。这有助于决定给患者服用什么药物来治疗重度抑郁症和其他精神疾病。
挑战
- 政府对新产品和仪器审批的监管十分严格
对产品功效和安全性的担忧促使大多数政府设立监管机构和政策来监督新医疗产品或测试的开发。这些医疗产品的使用必须通过严格的监管标准，以确保产品安全、经过充分研究且无不良反应。
最近的指南和修正案为制造商提供了充分的指导。食品、药品和行政管理等国际法规在医疗产品或测试进入市场的新版本中发挥着重要作用。因此，它可能成为市场的主要制约因素。因此，政府对新产品和仪器审批的严格监管可能会影响市场。
新冠肺炎疫情对亚太地区精神病学/抑郁症药物基因组学检测市场的影响
COVID-19 疫情对药物基因组学检测行业的扩张产生了有益的影响。由于该领域的研究活动暂时停止，再加上医院和诊断中心的患者流入量较低，疫情对药物基因组学市场的增长产生了负面影响。自 2020 年下半年以来，随着对某些药物的研究和 COVID-19 检测试剂盒的需求不断增加，药物基因组学实践一直很流行。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改进药物基因组学检测市场所涉及的技术和检测结果。
最新动态
- 2022 年 4 月，Blue Care Network (BCN) 启动了一项精准医疗计划。Blue Cross 个性化医疗利用药物基因组学或基因检测，根据对特定会员针对各种诊断（包括行为健康、心脏病学、心血管和肿瘤学）开具的药物的审查，为特定会员更有效地个性化和定制药物治疗。OneOme LLC 帮助 BCN 实现了其精准医疗计划目标，降低了总护理成本，并通过减少药物不良反应改善了患者的健康状况。这有助于该公司增强其产品组合。
- 2022 年 2 月，领先的高质量、高精度测序平台提供商 PacBio 宣布，它正在支持加拿大多伦多儿童医院 (SickKids) 使用 HiFi 全基因组测序 (HiFi WGS) 来识别可能与医疗和发育状况相关的遗传变异。使用 HiFi WGS 检查的样本之前曾使用短读 DNA 测序技术进行测序，但仍然缺乏对致病变异的识别。这有助于该公司提高其产品的使用率。
- 2022 年 7 月，根据美国退伍军人事务部 (VA) 对近 2,000 名退伍军人进行的一项全国性新研究，在有史以来规模最大的心理健康 PGx 随机对照试验中，当临床医生能够获得 Myriad Genetics, Inc. 的 GeneSight Psychotropic 测试结果时，重度抑郁症 (MDD) 的缓解率显著提高。这有助于该公司展示其在药物基因组学测试方面的进展。
- 2021 年 1 月，myDNA Life Australia Pty Ltd 宣布与总部位于美国休斯顿的消费者 DNA 测试公司 FamilyTreeDNA 及其母公司 Gene by Gene 合并，以彻底改变药物基因组学领域，使真正的个性化医疗成为现实，然后扩展到营养基因组学，提供可操作的个性化营养、健身和护肤建议。这有助于公司扩大业务。
亚太地区精神病学/抑郁症药物基因组学检测市场范围
亚太地区精神病学/抑郁症药物遗传学测试市场细分为类型、测试类型、基因类型、患者类型、产品、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按类型划分）
- 焦虑
- 情绪障碍
- 沮丧
- 双相情感障碍
- 精神病
- 饮食失调
根据类型，亚太地区精神病学/抑郁症药物基因组学测试市场分为焦虑症、情绪障碍、抑郁症、躁郁症、精神病和饮食失调。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按检测类型划分）
- 全基因组测序
- 基于染色体阵列的检测
根据测试类型，亚太地区精神病学/抑郁症药物遗传学测试市场分为全基因组测序和基于染色体阵列的测试。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按基因类型划分）
- CYP2C19
- CYP2C9 和 VKORC1
- CYP2D6
- HLA-B
- 高温气冷堆2A/C
- 人类白细胞抗原A
- CYP3A4
- SLC6A4
- 亚甲基四氢叶酸还原酶
- 通信技术
- 其他的
根据基因类型，亚太地区精神病学/抑郁症药物遗传学检测市场分为 CYP2C19、CYP2C9、VKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT 等。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按患者类型划分）
- 孩子
- 成人
- 老年
根据患者类型，亚太地区精神病学/抑郁症药物基因组学检测市场分为儿童、成人和老年人。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按产品划分）
- 仪器
- 耗材
- 软件与服务
根据产品类型，亚太地区精神病学/抑郁症药物基因组学测试市场分为仪器、消耗品以及软件和服务。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按最终用户划分）
- 医院和诊所
- 诊断实验室
- 学术及研究机构
- 其他的
根据最终用户，亚太地区精神病学/抑郁症药物基因组学检测市场分为医院和诊所、诊断实验室、学术和研究机构等。
- 亚太地区精神病学/抑郁症药物基因组学检测市场（按分销渠道划分）
- 直接招标
- 第三方分销
- 医院药房
- 其他的
根据分销渠道，亚太地区精神病学/抑郁症药物基因组学检测市场分为直接招标、第三方分销医院药房和其他。
亚太地区精神病学/抑郁症药物基因组学检测市场区域分析/见解
对亚太地区精神病学/抑郁症药物基因组学测试市场进行分析，并按类型、测试类型、基因类型、患者类型、产品、最终用户和分销渠道提供市场规模信息。
本市场报告涵盖的国家包括中国、日本、印度、韩国、新加坡、泰国、马来西亚、澳大利亚、越南、菲律宾、印度尼西亚和亚太地区其他国家。
2022 年，由于主要市场参与者的战略合作和产品发布不断增加，亚太地区将成为第三大市场。由于药物基因组学测试技术进步的提升，日本预计将实现增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太地区品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。
亚太地区精神病学/抑郁症药物基因组学检测的竞争格局和市场份额分析
亚太地区精神病学/抑郁症药物遗传学测试市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对亚太地区精神病学/抑郁症药物遗传学测试市场的关注有关。
亚太地区精神病学/抑郁症药物基因组学测试市场的一些主要参与者包括
- Genelex（Invitae 公司的一部分）
- Genewiz（Azenta Life Sciences 旗下子公司）
- MD 实验室
- BiogeneiQ 公司
- ONEOME 有限责任公司
- Myriad Genetics 公司
- 基因
- 城堡生物科学公司
- 太平洋生物科技
- 凯杰公司
- 赛默飞世尔科技公司
- AB-Biotics，SA
- Coriell 生命科学
- 欧陆科技
- Illumina 公司
- 动态 DNA 实验室
- 德国斯塔达制药有限公司
- 颜色
- 剂量
- Genomind 公司
- 健康观点
- myDNA Life 澳大利亚有限公司
- 哈德森阿尔法
- 索尼克医疗有限公司
研究方法：亚太地区精神病学/抑郁症药物基因组学检测市场
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of Asia-Pacific pharmacogenetic testing in psychiatry/depression market
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- type LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- market application coverage grid
- vendor share analysis
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insights
- REGULATIONS: ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
- AUSTRALIA
- SOUTH KOREA
- market overview
- drivers
- RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
- INITIATIVES TAKEN BY MANUFACTURERS
- GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
- INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
- GROWING MEDICAL TOURISM
- RESTRAINTS
- LACK OF STRONG CLINICAL EVIDENCE
- HIGH COST
- LACK OF REIMBURSEMENT
- OPPORTUNITIES
- TECHNOLOGICAL ADVANCEMENTS
- EMERGENCE OF NEW PLAYERS
- Untapped market
- CHALLENGES
- STRINGENT GOVERNMENT REGULATION
- SHORTAGE OF SKILLED PERSONNEL
- COVID-19 IMPACT ON ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY
- KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
- CONCLUSION:
- Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
- overview
- WHOLE GENOME SEQUENCING
- array-based TESTS
- Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
- overview
- cyp2c19
- CYP2C9 and VKORC1
- cyp2d6
- HLA-B
- htr2a/c
- HLA-A
- cyp3A4
- slc6a4
- MTHFR
- COMT
- others
- Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
- overview
- PRESCRIPTION DRUGS
- Over-the-counter medications
- RECREATIONAL DRUGS
- VITAMINS/NUTRACEUTICals
- ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
- overview
- SALIVA
- BLOOD
- ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY application
- overview
- DRUG DEVELOPMENT
- CLINICAL PRACTICE
- Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
- overview
- pharmaceutical and biotechnology companies
- HEALTHCARE PROVIDERS
- research centers and academic INSTITUTES
- others
- Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
- overview
- RETAIL PHARMACIES
- HOSPITAL PHARMACIES
- MAIL-ORDER PHARMACIES
- DIRECt-to-customer services
- ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, by Country
- overview
- Asia-Pacific
- JAPAN
- cHINA
- SOUTH KOREA
- INDIA
- AUSTRALIA
- SINGAPORE
- THAILAND
- MALAYSIA
- indonesia
- philipPines
- rest of asia-pacific
- Asia-Pacific pharmacogenetic testing in psychiatry/depression market: COMPANY landscape
- company share analysis: Asia-Pacific
- swot analysis
- company profile
- MYRIAD GENETICS, INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- THERMO FISHER SCIENTIFIC INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- STADA ARZNEIMITTEL AG
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- sonic healthcare
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- Illumina, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- AB-Biotics, S.A.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- 6.3 PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ALTHEADX
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- cnsdose
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- luminex corporation
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- mydna life australia pty ltd.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- PerkinElmer Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- R-Biopharm AG
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
表格列表
TABLE 1 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 2 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2019-2028 (USD MILLION)
TABLE 3 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 4 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 5 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 6 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 7 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 10 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 12 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 13 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 14 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 15 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 16 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 17 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 18 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 19 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 20 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 21 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 22 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 23 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 24 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 25 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 26 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 27 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 28 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 29 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 30 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 31 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 32 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 33 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 34 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 35 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 36 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 37 India PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 38 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 39 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 40 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 41 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 42 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 43 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 44 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 45 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 46 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 47 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 48 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 49 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 50 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 51 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 52 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 53 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 54 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 55 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 56 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 57 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 58 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 59 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 60 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 61 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 62 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 63 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 64 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 65 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 66 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 67 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 68 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 69 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 70 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 71 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 72 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 73 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 74 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 75 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 76 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 77 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 78 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 79 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
TABLE 80 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
TABLE 81 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD million)
TABLE 82 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD million)
TABLE 83 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD million)
TABLE 84 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD million)
TABLE 85 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD million)
TABLE 86 Rest of Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD million)
图片列表
FIGURE 1 Asia-Pacific PHARMACOGENETIC TESTIG IN PSYCHIATRY/DEPRESSION market: segmentation
FIGURE 2 Asia-Pacific pharmacogenetic testing in psychiatry/depression market: data triangulation
FIGURE 3 Asia-Pacific pharmacogenetic testing in psychiatry/depression market: DROC ANALYSIS
FIGURE 4 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: Region vs country MARKET ANALYSIS
FIGURE 5 Asia-Pacific pharmacogenetic testing in psychiatry/depression market: COMPANY RESEARCH ANALYSIS
FIGURE 6 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DBMR MARKET POSITION GRID
FIGURE 7 Asia-Pacific pharmacogenetic testing in psychiatry/depression market: MARKET APPLICATION COVERAGE GRID
FIGURE 8 Asia-Pacific pharmacogenetic testing in psychiatry/depression market: vendor share analysis
FIGURE 9 Asia-Pacific pharmacogenetic testing in psychiatry/depression market: SEGMENTATION
FIGURE 10 initiatives taken by manufacturers is expected to drive THE Asia-Pacific pharmacogenetic testing in psychiatry/depression market IN THE FORECAST PERIOD of 2021 to 2028
FIGURE 11 whole genome sequencing segment is expected to account for the largest share of the Asia-Pacific pharmacogenetic testing in psychiatry/depression market in 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
FIGURE 13 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2020
FIGURE 14 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 15 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 16 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2020
FIGURE 18 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
FIGURE 19 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
FIGURE 20 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
FIGURE 21 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2020
FIGURE 22 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
FIGURE 23 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 24 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2020
FIGURE 26 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
FIGURE 27 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 28 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 29 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2020
FIGURE 30 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 31 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 32 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2020
FIGURE 34 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 35 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
FIGURE 36 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 38 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 39 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 40 Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 42 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020-2028)
FIGURE 43 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 44 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 45 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 46 Asia-Pacific pharmacogenetic testing in psychiatry/DEPRESSION MARKET: company share 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
